Kapusta Daniel R, Thorkildsen Christian, Kenigs Velga A, Meier Eddi, Vinge Mette M, Quist Charlotte, Petersen Jørgen Søberg
Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112, USA.
J Pharmacol Exp Ther. 2005 Aug;314(2):652-60. doi: 10.1124/jpet.105.083436. Epub 2005 Apr 26.
In conscious rats, intravenous (i.v.) administration of the hexapeptide Ac-RYYRWK-NH(2), a partial agonist of the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor, produces a selective water diuresis without marked cardiovascular or behavioral effects. The present study examined the in vitro and in vivo pharmacodynamic profile of the novel and potentially metabolically stable NOP receptor ligand ZP120 (Ac-RYYRWKKKKKKK-NH(2)), which was created by conjugation of a structure-inducing probe (SIP) (i.e., K(6) sequence) to Ac-RYYRWK-NH(2). In cells transfected with human NOP receptors, both Ac-RYYRWK-NH(2) and ZP120 displaced [(3)H]N/OFQ (both peptides, pK(i) = 9.6), and similar to N/OFQ inhibited forskolin-induced cAMP formation (Ac-RYYRWK-NH(2), pEC(50) = 9.2; ZP120, 9.3; N/OFQ, 9.7). In the mouse vas deferens assay (MVD), Ac-RYYRWK-NH(2) and ZP120 behaved as partial agonists, inhibiting electrically induced contractions with similar pEC(50) values (9.0 and 8.6, respectively) but with submaximal efficacy compared with N/OFQ. In MVD, both peptides blocked the responses to N/OFQ, with ZP120 being approximately 50-fold more potent than Ac-RYYRWK-NH(2). In vivo, dose-response studies in rats showed that at doses (i.v. bolus or i.v. infusion) that produced a sodium-potassium-sparing aquaresis, ZP120 and Ac-RYYRWK-NH(2) elicited a mild vasodilatory response without reflex tachycardia. However, the renal responses to ZP120 were of greater magnitude and duration. Finally, each peptide blocked the bradycardia and hypotension to N/OFQ in conscious rats, but the effect of ZP120 was of much greater duration. Together, these findings demonstrate that ZP120 is a novel, functionally selective SIP-modified NOP receptor partial agonist with increased biological activity and sodium-potassium-sparing aquaretic activity, the actions of which may be useful in the management of hyponatremia/hypokalemia in water-retaining states.
在清醒大鼠中,静脉注射六肽Ac-RYYRWK-NH₂(一种痛敏肽/孤啡肽FQ(N/OFQ)肽(NOP)受体的部分激动剂)可产生选择性水利尿,而无明显的心血管或行为效应。本研究考察了新型且可能代谢稳定的NOP受体配体ZP120(Ac-RYYRWKKKKKKK-NH₂)的体外和体内药效学特征,该配体是通过将结构诱导探针(SIP)(即K₆序列)与Ac-RYYRWK-NH₂偶联而产生的。在转染了人NOP受体的细胞中,Ac-RYYRWK-NH₂和ZP120均可置换[³H]N/OFQ(两种肽的pKᵢ均为9.6),并且与N/OFQ类似,均可抑制福斯高林诱导的cAMP生成(Ac-RYYRWK-NH₂的pEC₅₀为9.2;ZP120为9.3;N/OFQ为9.7)。在小鼠输精管试验(MVD)中,Ac-RYYRWK-NH₂和ZP120表现为部分激动剂,以相似的pEC₅₀值(分别为9.0和8.6)抑制电诱导的收缩,但与N/OFQ相比,效能未达最大。在MVD中,两种肽均阻断对N/OFQ的反应,其中ZP120的效力比Ac-RYYRWK-NH₂强约50倍。在体内,大鼠的剂量反应研究表明,在产生保钠保钾性水利尿的剂量(静脉推注或静脉输注)下,ZP120和Ac-RYYRWK-NH₂可引起轻度血管舒张反应,而无反射性心动过速。然而,ZP120引起的肾脏反应在幅度和持续时间上更大。最后,每种肽均可阻断清醒大鼠对N/OFQ的心动过缓和低血压,但ZP120 的作用持续时间长得多。总之,这些发现表明ZP120是一种新型的、功能选择性的SIP修饰的NOP受体部分激动剂,具有增强的生物活性和保钠保钾性水利尿活性,其作用可能有助于治疗水潴留状态下的低钠血症/低钾血症。